JP2019519584A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519584A5 JP2019519584A5 JP2018568771A JP2018568771A JP2019519584A5 JP 2019519584 A5 JP2019519584 A5 JP 2019519584A5 JP 2018568771 A JP2018568771 A JP 2018568771A JP 2018568771 A JP2018568771 A JP 2018568771A JP 2019519584 A5 JP2019519584 A5 JP 2019519584A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- item
- patient
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 48
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 24
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 18
- 229960001467 bortezomib Drugs 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 14
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 13
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 13
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 13
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 13
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 13
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 13
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 13
- 229940068977 polysorbate 20 Drugs 0.000 claims description 13
- 208000023761 AL amyloidosis Diseases 0.000 claims description 12
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims description 12
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 12
- 108700028909 Serum Amyloid A Proteins 0.000 claims description 12
- 230000000747 cardiac effect Effects 0.000 claims description 12
- 229960004397 cyclophosphamide Drugs 0.000 claims description 12
- 229960003957 dexamethasone Drugs 0.000 claims description 12
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 12
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 12
- 229960004942 lenalidomide Drugs 0.000 claims description 12
- 229960001924 melphalan Drugs 0.000 claims description 12
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 12
- 229960004618 prednisone Drugs 0.000 claims description 12
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 102400001263 NT-proBNP Human genes 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 229960004679 doxorubicin Drugs 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 37
- 238000000034 method Methods 0.000 description 36
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022106974A JP2022121658A (ja) | 2016-06-30 | 2022-07-01 | アミロイドーシスを処置するための組成物 |
| JP2024108049A JP2024127990A (ja) | 2016-06-30 | 2024-07-04 | アミロイドーシスを処置するための組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357151P | 2016-06-30 | 2016-06-30 | |
| US62/357,151 | 2016-06-30 | ||
| PCT/US2017/040289 WO2018005967A1 (en) | 2016-06-30 | 2017-06-30 | Compositions for treating amyloidosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022106974A Division JP2022121658A (ja) | 2016-06-30 | 2022-07-01 | アミロイドーシスを処置するための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019519584A JP2019519584A (ja) | 2019-07-11 |
| JP2019519584A5 true JP2019519584A5 (https=) | 2020-08-13 |
Family
ID=59351103
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568771A Withdrawn JP2019519584A (ja) | 2016-06-30 | 2017-06-30 | アミロイドーシスを処置するための組成物 |
| JP2022106974A Withdrawn JP2022121658A (ja) | 2016-06-30 | 2022-07-01 | アミロイドーシスを処置するための組成物 |
| JP2024108049A Pending JP2024127990A (ja) | 2016-06-30 | 2024-07-04 | アミロイドーシスを処置するための組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022106974A Withdrawn JP2022121658A (ja) | 2016-06-30 | 2022-07-01 | アミロイドーシスを処置するための組成物 |
| JP2024108049A Pending JP2024127990A (ja) | 2016-06-30 | 2024-07-04 | アミロイドーシスを処置するための組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190169280A1 (https=) |
| EP (1) | EP3478713B1 (https=) |
| JP (3) | JP2019519584A (https=) |
| CY (1) | CY1125536T1 (https=) |
| DK (1) | DK3478713T3 (https=) |
| ES (1) | ES2914781T3 (https=) |
| HR (1) | HRP20220979T8 (https=) |
| HU (1) | HUE059400T2 (https=) |
| LT (1) | LT3478713T (https=) |
| MA (1) | MA45552A (https=) |
| PL (1) | PL3478713T3 (https=) |
| PT (1) | PT3478713T (https=) |
| RS (1) | RS63446B1 (https=) |
| SI (1) | SI3478713T1 (https=) |
| SM (1) | SMT202200261T1 (https=) |
| WO (1) | WO2018005967A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7217287B2 (ja) * | 2018-03-23 | 2023-02-02 | プロシーナ バイオサイエンシーズ リミテッド | アミロイド症の処置および予防 |
| JP2022520572A (ja) * | 2019-02-12 | 2022-03-31 | プロシーナ バイオサイエンシーズ リミテッド | 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置 |
| EP4582446A3 (en) * | 2019-03-05 | 2025-08-13 | Prothena Biosciences Limited | Methods of treating al amyloidosis |
| EP4022062A1 (en) * | 2019-08-30 | 2022-07-06 | Alnylam Pharmaceuticals, Inc. | Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy |
| CA3187944A1 (en) * | 2020-06-22 | 2021-12-30 | Ngm Biopharmaceuticals, Inc. | Lair-1-binding agents and methods of use thereof |
| TW202332465A (zh) * | 2021-01-29 | 2023-08-16 | 愛爾蘭商普羅希那生物科學有限公司 | 治療al類澱粉變性症之方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| DK2237803T3 (en) | 2007-12-28 | 2015-10-05 | Prothena Biosciences Ltd | Treatment and prophylaxis of amyloidosis |
| CN107233569B (zh) | 2011-10-25 | 2021-08-31 | 普罗西纳生物科学有限公司 | 抗体制剂和方法 |
-
2017
- 2017-06-30 ES ES17740200T patent/ES2914781T3/es active Active
- 2017-06-30 PL PL17740200.5T patent/PL3478713T3/pl unknown
- 2017-06-30 SI SI201731146T patent/SI3478713T1/sl unknown
- 2017-06-30 MA MA045552A patent/MA45552A/fr unknown
- 2017-06-30 SM SM20220261T patent/SMT202200261T1/it unknown
- 2017-06-30 HR HRP20220979TT patent/HRP20220979T8/hr unknown
- 2017-06-30 US US16/314,143 patent/US20190169280A1/en not_active Abandoned
- 2017-06-30 RS RS20220716A patent/RS63446B1/sr unknown
- 2017-06-30 PT PT177402005T patent/PT3478713T/pt unknown
- 2017-06-30 DK DK17740200.5T patent/DK3478713T3/da active
- 2017-06-30 EP EP17740200.5A patent/EP3478713B1/en active Active
- 2017-06-30 HU HUE17740200A patent/HUE059400T2/hu unknown
- 2017-06-30 LT LTEPPCT/US2017/040289T patent/LT3478713T/lt unknown
- 2017-06-30 WO PCT/US2017/040289 patent/WO2018005967A1/en not_active Ceased
- 2017-06-30 JP JP2018568771A patent/JP2019519584A/ja not_active Withdrawn
-
2020
- 2020-09-25 US US17/032,884 patent/US20210079078A1/en not_active Abandoned
-
2022
- 2022-07-01 JP JP2022106974A patent/JP2022121658A/ja not_active Withdrawn
- 2022-08-08 CY CY20221100542T patent/CY1125536T1/el unknown
-
2024
- 2024-07-04 JP JP2024108049A patent/JP2024127990A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12296008B2 (en) | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | |
| JP2019519584A5 (https=) | ||
| Malone et al. | The immune system and stroke: from current targets to future therapy | |
| RU2721910C2 (ru) | Фармацевтическая композиция, предназначенная для применения для предупреждения и/или лечения заболевания, которое развивается или прогрессирует вследствие снижения или утраты активности фактора свертывания крови viii и/или активированного фактора свертывания крови viii | |
| AU2016250388B2 (en) | Treatment for rheumatoid arthritis | |
| JP2021526534A5 (https=) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| EP3487881B1 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| JP2018529635A5 (https=) | ||
| JP2018515493A5 (https=) | ||
| JP2015525798A5 (https=) | ||
| JP2020502219A5 (https=) | ||
| CN105251004A (zh) | 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物 | |
| JP2019532970A5 (https=) | ||
| KR20200010472A (ko) | 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임 | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| JP2020502218A5 (https=) | ||
| JP2022520572A5 (https=) | ||
| JP2022520572A (ja) | 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置 | |
| JP2024522620A5 (https=) | ||
| JP2023551733A (ja) | 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの併用免疫療法 | |
| US20160022777A1 (en) | Combination therapy with il-12 | |
| US20230338496A1 (en) | Vaccination against diabetes, obesity and complications thereof | |
| US11623003B2 (en) | Vaccination against diabetes, obesity and complications thereof | |
| JP2021518393A5 (https=) |